omniture
尧唐(上海)生物科技有限公司

Latest News

YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia

SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage gene editing company...

2025-01-21 10:34 2184

YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR

SHANGHAI, Dec. 21, 2024 /PRNewswire/ -- YolTech Therapeutics today announced updated data from its ...

2024-12-21 16:23 3507

YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China

SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene edit...

2024-08-27 18:30 1233

YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1

SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene edit...

2024-08-22 18:00 1733

First Patient Dosed in Phase I Clinical Trial of YOLT-201

SHANGHAI, July 11, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo ...

2024-07-11 20:11 1822

YolTech and KACTUS Join Forces to Propel Innovative DNA editing system in Greater China

Strategic Partnership to Advance Gene Editing Technologies in Biomedical Applications SHANGHAI, Ju...

2024-06-19 09:00 1678

First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

SHANGHAI, April 2, 2024 /PRNewswire/ -- YolTech Therapeutics announced that the first patient has b...

2024-04-02 20:00 1480

YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean

SHANGHAI, March 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a trailblazing biopharmaceutical com...

2024-03-27 20:00 1568

YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024

SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company pioneering inin vi...

2024-03-13 20:00 1553

Landmark Clinical Approval for YOLT-201 Obtained by the NMPA

SHANGHAI, March 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo ...

2024-03-04 20:00 780

YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developingin vivo ge...

2024-01-02 20:30 1544

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient...

2023-12-17 23:15 1664